Sanofi To Run Consultations Over Restart Of Hydroxychloroquine Trials

Sanofi said on Wednesday it would review available information and run consultations before deciding whether to enroll patients again for its COVID-19-related hydroxychloroquine trials.

The French drugmaker said on May 29 it had stopped recruiting new COVID-19 subjects for two clinical trials on hydroxychloroquine until concerns about safety are cleared up following a decision by the World Health Organization to pause a large trial.

The WHO said earlier in the day the trial would resume.

"We will review available information and run consultations in the coming days to reassess our position," a spokesman with Sanofi said.

(Reuters)